280 related articles for article (PubMed ID: 16013910)
1. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
Greco KE; Tune LE; Brown FW; Van Horn WA
J Clin Psychiatry; 2005 Jul; 66(7):928-9. PubMed ID: 16013910
[TBL] [Abstract][Full Text] [Related]
2. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
3. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
4. Single-dose ziprasidone associated with QT interval prolongation.
Witsil JC; Zell-Kanter M; Mycyk MB
Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
[TBL] [Abstract][Full Text] [Related]
5. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
6. Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment.
Tümüklü MN; Tümüklü MM; Nesterenko V; Jayathilake K; Beasley CM; Meltzer HY
J Clin Psychopharmacol; 2019; 39(2):100-107. PubMed ID: 30707117
[TBL] [Abstract][Full Text] [Related]
7. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
8. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
[TBL] [Abstract][Full Text] [Related]
9. QT interval duration and dispersion in children and adolescents treated with ziprasidone.
Correll CU; Lops JD; Figen V; Malhotra AK; Kane JM; Manu P
J Clin Psychiatry; 2011 Jun; 72(6):854-60. PubMed ID: 21457682
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
[TBL] [Abstract][Full Text] [Related]
11. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
[TBL] [Abstract][Full Text] [Related]
12. [QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
Finzel M; Fric M; Laux G
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S178-80. PubMed ID: 15570546
[TBL] [Abstract][Full Text] [Related]
13. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
Kelly DL; Love RC
Psychopharmacol Bull; 2001; 35(4):66-79. PubMed ID: 12397857
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
16. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
[TBL] [Abstract][Full Text] [Related]
17. A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
Muzyk AJ; Rivelli SK; Jiang W; Heinz H; Rayfield A; Gagliardi JP
Drug Saf; 2012 Sep; 35(9):725-31. PubMed ID: 22876752
[TBL] [Abstract][Full Text] [Related]
18. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
19. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Potkin SG; Preskorn S; Hochfeld M; Meng X
J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.
Klein LR; Driver BE; Miner JR; Martel ML; Hessel M; Collins JD; Horton GB; Fagerstrom E; Satpathy R; Cole JB
Ann Emerg Med; 2018 Oct; 72(4):374-385. PubMed ID: 29885904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
